Irinotecan
Newer drugs with single-agent anti-tumor activity for example, gemcitabine, paclitaxel, docetaxel, vinorelbine, irinotecan and topotecan ; are being added to conventional regimens with evidence of modest tumor response and survival.
Purpose: The main objectives of this phase I and pharmacokinetic, open-label study were to characterize the principal toxicities and determine the maximum tolerated dose of the multitargeted antifolate pemetrexed administered in combination with irinotecan. The study also sought to detect major pharmacokinetic drug-drug interactions between these agents and preliminary evidence of antitumor activity in patients with advanced solid malignancies. Experimental Design: Pemetrexed was administered as a 10-min i.v. infusion followed by irinotecan given i.v. over 90 min every 3 weeks to patients with advanced solid malignancies. The study objectives were first pursued in heavily pretreated patients and then in lightly pretreated patients who also received vitamin supplementation. Results: Twenty-three heavily pretreated patients enrolled in the first stage of the study, and the maximum tolerated dose level of pemetrexed irinotecan without vitamin supplementation was 400 250 mg m2; further dose escalation was precluded by severe neutropenia that was protracted and or associated with fever. In the second stage of the study, 28 lightly pretreated patients were administered pemetrexed irinotecan with vitamin supplementation; these patients tolerated pemetrexed irinotecan at a dose level of 500 350 mg m2, which reflected clinically relevant single-agent doses of both agents. No major pharmacokinetic interactions between the agents were evident. Four patients, two patients each with colorectal cancer refractory to fluoropyrimidines and advanced mesothelioma, had partial responses. Conclusions: The pemetrexed irinotecan regimen is well tolerated in patients with advanced solid malignancies at clinically relevant single-agent doses. The recommended dose level of pemetrexed irinotecan for subsequent disease-directed evaluations involving lightly pretreated patients is 500 350 mg m2 every 3 weeks with vitamin supplementation.
The Journal of Nudear Medicine 34 6 1993 Vol. No. June.
Online Pharmacy
All aspects of drug receptors. Pharmacology and therapeutic use of drugs affecting diseases of bones, joints and muscles, e.g. antirheumatics.
J.J.F. Schroots, J.E. Birren, and A. Svanborg, Eds. Nine experts present their ideas about healthy aging as the starting point for the future of old age. They set goals for research, scholarship, and service. 1989 Est. 190pp. pre-pub. .50.
I know it has had some good results n early phase trials, but from what i have read that was when using it with irinotecan the protocol i on now and isdn.
The combination AMK-RIF given for 3 months cured the M. ulcerans disease and was not followed by relapse within the 6 months after treatment completion The oral combination RIF + SPX + Clari was less rapidly active and followed by relapse RIF alone stabilized the disease and selected resistant mutants in the hands of Marsollier & Carbonnelle AAC 2003: 47: 1228-32.
Over 30-minutes. The initial dose of Avastin should be administered following chemotherapy, all subsequent doses can be given before or after chemotherapy. Avastin should not be administered as an intravenous push or bolus. Avastin infusions should not be administered or mixed with dextrose or glucose solutions see SPC, sections 4.2 and 6.2 ; . Instructions for use and handling are detailed in the SPC see section 6.6 ; . Pharmacokinetics Serum bevacizumab concentrations were measured in 8 different clinical studies in patients with different solid tumours. In all clinical trials, bevacizumab was administered as an IV infusion. The rate of infusion was based on tolerability, with an initial infusion duration of 90 minutes. More extensive sampling was made in one Phase I study AVF0737g ; , where single and multiple doses from 0.1 mg kg to 10 mg kg were evaluated. In the remaining Phase studies mainly peak and trough bevacizumab concentrations were determined, where doses ranged from 3 to 20 mg kg at intervals of two or three weeks. Four of the studies can be defined as dose-escalation studies AVF0737g, AVF0776g, AVF0757g, AVF0780g ; with bevacizumab as monotherapy or in combination with cytotoxic agents. Only two of the clinical studies have been performed with the target dose of 5 mg kg 2 weeks AVF0780g, AVF02107g ; . No clinical studies were performed to specifically investigate the pharmacokinetics. Rather, pharmacokinetic data were obtained as part of the clinical safety and efficacy studies. A summary of bevacizumab pharmacokinetic parameters by study is shown in Table 2. For concomitantly administered drugs, 5-FU was analysed by HPLC and GC-MS, irinotecan was analysed by HPLC, capecitabine was analysed by tandem mass LC-MS. All of the above analyses are well validated and the methods seem suitable for their purposes. Pharmacokinetic data was analysed using standard two-compartment and one-compartment methods. Terminal elimination half-life was also addressed using non-compartmental methods. Population pharmacokinetics was performed using a mixed-effects model. The pharmacokinetic data were primarily derived using the original formulation of bevacizumab. The manufacturing process changes were not considered to alter the pharmacokinetics of bevacizumab and isradipine.
Inputs could reach lamina I neurons over two routes: directly on their dendrites in lamina I and indirectly via an excitatory interneuron Gobel, 1979 ; . Recently, a number of studies using several different experimental approaches have addressed the question of the termination sites of A6 and C primary axons in laminae I and II. These studies have led to two different interpretations as to how these axons are distributed in these laminae. One interpretation is based on light La Motte, 1977 ; and electron microscopical EM ; Ralston and Ralston, 1979 ; degeneration studies as well as on studies in which physiologically identified AS primary axons were injected intra-axonally with HRP Light and Perl, 1979 ; and electrophysiological studies of neurons in laminae I and II Kumazawa and Perl, 1978; Light et al., 1979 ; . These studies suggest that C primary axons terminate predominantly in lamina II and that AS primary axons terminate in lamina I. The second interpretation is based on EM degeneration studies Gobel and Binck, 1977 ; and on studies in which primary axons were filled with HRP Gobel and Falls, 1979 ; and suggests that lamina I is an important termination site of C primary axons and lamina II is an important termination site of A6 primary neurons. While neither of these interpretations in their original conception precluded the other, they are nonetheless frequently thought of as mutually exclusive and remain at the heart of one of the major issues in the neural circuitry of the dorsal horn. The present study was undertaken because earlier independent studies identified two kinds of primary endings in lamina I. One was a very small ending Gobel and Binck, 1977; Gobel and Hockfield, 1977 ; and the other was a relatively large ending Light and Perl, 1979; Ralston and Ralston, 1979 ; . Such observations suggested that lamina I may not simply receive the terminal arbors of a single kind of primary axon but that two or more different kinds of primary axons may terminate there. If this were in fact the case, it would help to clarify some of the earlier above mentioned disparate views which intimated that lamina I received the terminal arbors of only a single kind of primary neuron. Recently, horseradish peroxidase HRP ; has been applied to the central portions of severed dorsal roots in order to fill primary axons and demonstrate different morphological aspects of primary axons in the spinal cord Light and Perl, 1977; Proshansky and Egger, 1977; Beattie et al., 1978; Gobel and Falls, 1979 ; . This method has several important advantages over more traditional degenerative techniques for studying primary axons in the spinal cord. First, filling of the primary axons with HRP occurs relatively quickly. This makes it possible to use short postoperative survival times following dorsal root rhizotomy, i.e., less than 1 day, so that primary axons can be viewed before they fragment or become detached from their synaptic connections. This obviates the difficulties in interpreting small endings as such or as degenerating fragments of larger endings. Second, it displays large numbers of primary endings in contrast to the relatively small number of degenerating primary endings seen at any given postoperative survival time since all primary axons do not degenerate at the same time. Third, primary endings can be viewed in the light microscope as well as in the electron microscope.
Budgetary resources to finance exports, but mainly to the benefit of large exporting firms. In 1997 a Trade Promotion Agency was created with the task of promoting exports of small and medium-sized firms. Although it is still early to assess its effectiveness, preliminary evaluations suggest that it made a modest contribution. Overall, the result of Brazilian export promotion policies has not been very encouraging in terms of diversifying either exports or exporters. Although the firm concentration of exports is significantly lower than in the case of Argentina, nearly two thirds of Brazilian total exports are accounted for by only 500 firms. In the realm of foreign trade negotiations Brazil has followed a predominantly defensive strategy. Its emphasis on the formation of a customs union with its regional partners MERCOSUR ; has been dwarfed by its reluctance to engage in deeper integration commitments that may reduce its policy discretion. Moreover, Brazilian negotiators have been typically reluctant to take stock of prevailing asymmetries in size, industrial development and institutional and financial capabilities, and to devise policies apt to compensate these imbalances. Brazilian trade policies have been even more defensive in North-South preferential negotiations. Since the offensive interests of Brazil lay mostly in areas that are sensitive in the US and the EU the same is true the other way round ; , the role of Brazil in the FTAA and EU-MERCOSUR negotiations has been eminently defensive. In coincidence with the size of the Brazilian economy and the diversification of its regional trade pattern, trade diplomacy has been increasingly active in the multilateral arena, promoting new coalitions aimed at strengthening developing countries' bargaining power. Markwald 2006 ; points out that structural features such as a relatively low foreign trade coefficient and the regional and commodity composition of foreign trade flows help to account for the priority which Brazilian trade policies has given to multilateral and regional negotiations, as well as the strength and influence of defensive import-competing interests. In effect, import-competing sectors have enjoyed relatively high protection and generous government incentives. This has been the case with very influential industries such as motor vehicles and textiles and clothing, which have been sheltered from foreign competition and have received generous government support to penetrate foreign markets. As far as export-oriented sectors are concerned, while agribusiness has become internationally very competitive without the need of public support, industrial exporters such as the steel and aircraft industries ; have grown fast in a context of heavy dependence on public sector export finance and special import regimes. While internationally competitive agribusiness has most of its offensive interests in developed country markets a fact that partly accounts for its lack of enthusiasm with MERCOSUR ; , most industrial sectors with offensive export interest are heavily dependent from regional or the US markets. There is no doubt that since the mid-1990s the balance of influence of these sectors has changed significantly, with agribusiness gaining more leverage in public debates and policy-making. However, this has yet failed to be fully reflected in a new trade policy approach. In effect, the predominant Brazilian policies still regard trade negotiations particularly North-South ; as a source of threats rather than opportunities and ivermectin.
Yon chay lou sou do bt yo tou bouke. 2. Ni bt yo, ni zidl yo tonbe ansanm at a. Zidl yo pa ka delivre ata bt k'ap pote yo a. Lnmi ap depte yo tankou moun yo f prizonye. 3. Nou menm fanmi Jakb yo, ti rs ki rete nan fanmi Izrayl la, nou menm mwen te pote nan men depi jou nou te ft la, nou menm mwen te soutni depi nan vant manman nou an, koute sa m'ap di nou byen: 4. M'ap toujou aji konsa ak nou jouk n'a vye granmoun. M'ap toujou soutni nou jouk n'a gen cheve blan. M'a pote nou nan men m' jan m' te toujou f l' la. M'a pran nou sou kont mwen, m'a delivre nou. 5. Ak ki moun nou ta konpare m'? Ki moun nou ka di ki sanble m'? Ki moun nou ka mete b kote m' ki tankou m'? 6. Gen moun ki pran l nan pch yo, yo peze ajan nan balans, yo peye yon fv pou f yon bondye pou yo. Lfini, yo mete ajenou devan l', yo adore l'. 7. Yo leve l' mete sou zepl yo, yo pote l' ale. Yo mete l' kanpe yon kote, epi li rete la. Kote yo mete l' la, li pa ka deplase. Yo mt lapriy nan pye l' kont k yo, li pa ka reponn! Li pa ka delivre yo l yo nan tray. 8. Pa janm bliye sa! Mete gason sou nou! Nou menm k'ap f peche, kalkile tou sa nou f! 9. Chonje tou sa ki te rive nan tan lontan. Rekont se mwen menm sl ki Bondye. Pa gen lt! Se mwen sl ki Bondye. Nanpwen tankou m'! 10. Depi nan konmansman, mwen te di jan sa pral ye. Depi davans mwen te f nou konnen sa ki tapral rive. Mwen te di plan travay mwen gen pou rive ft vre. M'ap f tou sa mwen te vle f a. 11. Mwen rele yon nonm mwen te chwazi soti nan yon peyi byen lwen b soly leve. Tankou yon malfini, li pral vini, li pral f travay mwen ba l' f Depi mwen di yon bagay, se pou l' ft. Depi mwen f lide f yon bagay, fk li ft. 12. Koute sa m'ap di nou, bann tt di, nou menm ki pa soti pou f sa ki dwat: 13. M'ap f jou delivrans nou an pwoche. Li pa lwen rive. Mwen p'ap mize vin delivre nou. Mwen pral delivre mn Siyon. Mwen pral f pp Izrayl la w pouvwa mwen.
Figure 1. Progressive decline of cell function in the UK Prospective Diabetes Study. Adapted from the UK Prospective Diabetes Study Group.2 and kaletra.
Period of 2 months. Of these, 33 patients were aged at least 70 years old. Fifteen patients underwent direct major LR without postoperative chemotherapy. Eighteen patients received only the LVFU2 regimen combined with irinotecan FOLFIRI protocol ; because of either ASA score 3 n 12 ; patients refusal of surgery n 6 ; . For the two groups, global survival was calculated using the Kaplan Meier method, and cause of death was examined. No patient was lost to follow-up or died of a cause other than colorectal cancer disease during a median observation time of 49 months. Mortality and morbidity of group 1 were 0% and 33%, respectively. All patients in group 2 died during the observation time. Survival at 1, 2 and 5 years of all 33 patients were 91%, 61% and 23%, respectively. The median survival rate was 28 months. Survival at 1 and 2 years for groups 1 and 2 were 73% and 50% P 0.04 ; and 47% and 15% P 0.05 ; , respectively. The median survival for groups 1 and 2 was 22 and 12 months, respectively P 0.03 ; . Our series indicated that exclusive major LR for HMCC in elderly patient can be safe and can improve survival. Patient age is a useful prognostic factor for prediction of postoperative liver failure. Thus, surgeons use less aggressive procedures because of higher comorbidity rates [3]. As a result, we found that postoperative complications and operative mortality rates after major LR did not differ from those in younger patients [4]. Surgical resection of HMCC improved survival because the benefit of major LR was not offset by high postoperative mortality. In fact, patients 70 years old who were eligible for surgery but who are treated exclusively by chemotherapy had a reduced life expectancy. Surgical eligibility is classically determined by number and location of tumors, as for younger patients [5]. In our experience, selected elderly patients with HMCC benefited from resection as much as young patients, and age alone may not be a contraindication to surgery. Association with thermoablation by radiofrequency could raise the limits of management of multimetastatic liver in the elderly. O. Turrini1 * , J. Guiramand1, V. Moutardier1, F. Viret2, E. Bories3, M. Giovannini3, N. Pernoud4, J.-L. Blache4 & J.-R. Delpero1.
International Head Public Policy F. Hoffmann-La Roche Ltd Head of Department of Education and Research Ministry of Health of the Czech Republic European Observatory on Health Care Systems and kaon.
Fur Analytik, Bergheim, Germany ; by an assay validated for human plasmas. The principle of the method was protein precipitation of homogenate samples, followed by high performance liquid chromatography with fluorescence detection. The results of the fluorescence detection could be brought into correlation to the concentration of irinotecan in tissue samples and processed homogenates. 2.6. General procedure.
The present phase i ii study was designed to determine the maximum tolerated dose mtd ; , the recommended dose and the safety profile of irinotecan when combined with the 5-fu fa mayo clinic schedule every four weeks in the treatment of advanced crc and kato.
To investigate this possibility, we isolated DNA from commercially available human serum Sigma ; by the two different methods. The DNA was then separated by polyacrylamide gel electrophoresis and stained with ethidium bromide, as shown in Fig. 1. As expected, the serum contained DNA fragments the size of nucleosomal DNA, which were resolved in an 8% polyacrylamide gel as indicated by the arrows in Fig. 1 ; , and larger DNA, which remained near the sample wells of the gel. Interestingly, much smaller amounts of the low-molecularweight DNA were observed when DNA was isolated by the Qiagen method Fig. 1, lane 4 ; . The only species that was detected was DNA in the size of mononucleosomes. DNA fragments that were in the size of di- and trinucleosomes were not seen. The most abundant DNA detected in the Qiagen preparation was the high-molecular-weight DNA, which remained unresolved and near the sample wells in the gel. In contrast, DNA in the size of mono-, di-, and trinucleosomes was readily detected in the serum DNA isolated by the G R method Fig. 1, lanes 2 and 3 ; when DNA was resolved in the gel, with very little highmolecular-weight DNA remaining near the well. There was less high-molecular-weight DNA remaining near the sample wells even when DNA was isolated from three times more serum by the G R method Fig. 1, lane 3 ; compared with the DNA isolated by the Qiagen method Fig. 1, lane 4 ; . These data clearly demonstrate that the DNA isolated by the Qiagen method was enriched in higher molecular weight DNA that remained unresolved in an 8% polyacrylamide gel, whereas the DNA isolated by the G R method was enriched in shorter, fragmented DNA. It has been suggested that there are two categories of circulating DNA 3 ; . One is large, genomic DNA, mostly derived from necrotic or hematopoietic cells; the other and irinotecan.
N. Mansencal 1 , F. Digne 1 , E. Mitry 2 , J.F. Forissier 1 , T. Joseph 1 , P. Lacombe 1 , P. Rougier 2 , O. Dubourg 1 . 1 Service de Cardiologie, 2 Service de gastro-entrologie, Hpital Ambroise Par, Boulogne, France Background: Several studies have demonstrated that serotonin and chemotherapy were associated with the progression of carcinoid heart disease CHD ; , without echocardiographic examination of the left-CHD. The aim of this prospective study was to assess the role of patent foramen ovale in the progression of right- and leftCHD. Method: In 30 consecutive patients mean age 58 years, range 40-74, 50% women ; with carcinoid syndrome, we performed serial 77 ; echocardiographic studies. The echocardiographic following parameters were systematically assessed: 1 ; right-CHD, 2 ; left-CHD, 3 ; right to left shunting through a patent foramen ovale PFO ; using contrast echocardiography at rest and after cough test or Vasalva maneuver. Results: Mean follow-up was 24 months range: 12-48 months ; . At baseline, echocardiography revealed 10 pts 33% ; with right-CHD and 4 pts 13% ; with left-CHD Table ; . At the end of follow-up, the incidence of right-CHD, left-CHD was respectively 53% 16 pts ; and 33% 10 pts ; . The baseline and follow-up frequencies of PFO were respectively 27% 8 pts ; and 43% 13 pts ; . The presence of PFO was strongly associated with the progression of both right- and left-CHD p 0.001 ; . The metabolite of serotonin urinary 5-HIAA, p 0.002 ; and plasmatic chromogranin A p 0.002 ; levels were also predictive factors of progression but not chemotherapy p 0.7 and kava.
|
